A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)
Phase of Trial: Phase IV
Latest Information Update: 28 May 2018
At a glance
- Drugs Follitropin alfa/lutropin alfa (Primary)
- Indications Female infertility
- Focus Adverse reactions
- Sponsors Merck KGaA
- 22 May 2018 Status changed from recruiting to completed
- 12 Apr 2018 Planned End Date changed from 1 May 2018 to 31 May 2018.
- 12 Apr 2018 Planned primary completion date changed from 1 May 2018 to 31 May 2018.